Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 17

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 1
Chunk 17
---
 that enables us to both generate clinically relevant insights that may not be possible with narrower testing approaches, and contribute high-quality molecular information back to providers and to our database. We offer large-panel solid tumor and hematologic testing through multiple assays, with our core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. Our current offerings also include liquid biopsy (xF), whole exome (xE), and hereditary cancer risk (xG). With our acquisition of Ambry in February 2025, we believe we have an opportunity to further expand and enhance our inherited risk screening capabilities for cancer patients. We are also currently validating a treatment response monitoring assay. Our oncology tests are differentiated not only because of their breadth, but also because in many cases they are connected to clinical data, which allows us to account for the drugs the patient took historically, how they responded, and for which clinical trials they are actually eligible. We endeavor to not recommend drugs for which a patient has been previously prescribed in a prior line of therapy and failed, and not recommend clinical trials they are not eligible to participate in, based on the inclusion or exclusion criteria of the trial. 

21

The following table lists our current oncology test offerings:

    Lab Tests 
    Launch Year
    Description

    Oncology tests

    Tempus|xT
    2017
    •Designed to detect actionable oncologic targets by sequencing tumor tissue samples•Typically associated with incidental germline testing for

    matched normal saliva or blood samples, when available

    •Fourth generation test that covers648 genes at 500x coverage spanning approximately 3.6 Mb of genomic space

    •Includes full TCR, BCR, and HLA typing for immuno- oncology, or IO, signatures

    •Detects TMB, MSI, and fusions

    •The test has an approximately 10-day quoted turnaround time.

    •In our analytical validation, we demonstrated sensitivities >98% for SNVs,>92% for rearrangements / fusions, >92% for CNVs and indels, and 99.9% for MSI.

    •Premarket approval (PMA) obtained from the FDA in April 2023

    •Awarded Advanced Diagnostic Laboratory Test (ADLT) status

    Tempus|xE
    2018
    •A whole exome cancer assay designed to identify actionable onc